BACKGROUND: Randomized trials have found that alvimopan hastens return of bowel function and reduces length of stay (LOS) by 1 day among patients undergoing colorectal surgery. However, its effectiveness in routine clinical practice and its impact on hospital costs remain uncertain. STUDY DESIGN: We performed a retrospective cohort study of patients undergoing elective colorectal surgery in Washington state (2009 to 2013) using data from a clinical registry (Surgical Care and Outcomes Assessment Program) linked to a statewide hospital discharge database (Comprehensive Hospital Abstract Reporting System). We used generalized estimating equations to evaluate the relationship between alvimopan and outcomes, and adjusted for patient, operative, and management characteristics. Hospital charges were converted to costs using hospital-specific charge to cost ratios, and were adjusted for inflation to 2013 US dollars. RESULTS: Among 14,781 patients undergoing elective colorectal surgery at 51 hospitals, 1,615 (11%) received alvimopan. Patients who received alvimopan had a LOS that was 1.8 days shorter (p < 0.01) and costs that were $2,017 lower (p < 0.01) compared with those who did not receive alvimopan. After adjustment, LOS was 0.9 days shorter (p < 0.01), and hospital costs were $636 lower (p = 0.02) among those receiving alvimopan compared with those who did not. CONCLUSIONS: When used in routine clinical practice, alvimopan was associated with a shorter LOS and limited but significant hospital cost savings. Both efficacy and effectiveness data support the use of alvimopan in routine clinical practice, and its use could be measured as a marker of higher quality care.
BACKGROUND: Randomized trials have found that alvimopan hastens return of bowel function and reduces length of stay (LOS) by 1 day among patients undergoing colorectal surgery. However, its effectiveness in routine clinical practice and its impact on hospital costs remain uncertain. STUDY DESIGN: We performed a retrospective cohort study of patients undergoing elective colorectal surgery in Washington state (2009 to 2013) using data from a clinical registry (Surgical Care and Outcomes Assessment Program) linked to a statewide hospital discharge database (Comprehensive Hospital Abstract Reporting System). We used generalized estimating equations to evaluate the relationship between alvimopan and outcomes, and adjusted for patient, operative, and management characteristics. Hospital charges were converted to costs using hospital-specific charge to cost ratios, and were adjusted for inflation to 2013 US dollars. RESULTS: Among 14,781 patients undergoing elective colorectal surgery at 51 hospitals, 1,615 (11%) received alvimopan. Patients who received alvimopan had a LOS that was 1.8 days shorter (p < 0.01) and costs that were $2,017 lower (p < 0.01) compared with those who did not receive alvimopan. After adjustment, LOS was 0.9 days shorter (p < 0.01), and hospital costs were $636 lower (p = 0.02) among those receiving alvimopan compared with those who did not. CONCLUSIONS: When used in routine clinical practice, alvimopan was associated with a shorter LOS and limited but significant hospital cost savings. Both efficacy and effectiveness data support the use of alvimopan in routine clinical practice, and its use could be measured as a marker of higher quality care.
Authors: David R Flum; Nancy Fisher; Jeffery Thompson; Miriam Marcus-Smith; Michael Florence; Carlos A Pellegrini Journal: Surgery Date: 2005-11 Impact factor: 3.982
Authors: Conor P Delaney; Christopher Craver; Melinda M Gibbons; Amy W Rachfal; Christine J VandePol; Suzanne F Cook; Sara A Poston; Michael Calloway; Lee Techner Journal: Ann Surg Date: 2012-04 Impact factor: 12.969
Authors: E R Viscusi; S Goldstein; T Witkowski; A Andonakakis; R Jan; K Gabriel; W Du; L Techner; B Wallin Journal: Surg Endosc Date: 2005-12-07 Impact factor: 4.584
Authors: Stephanie R Earnshaw; Teresa L Kauf; Cheryl McDade; Michele H Potashman; Cassandra Pauyo; Emily S Reese; Anthony Senagore Journal: J Am Coll Surg Date: 2015-08-15 Impact factor: 6.113
Authors: Kirk Ludwig; Warren E Enker; Conor P Delaney; Bruce G Wolff; Wei Du; John G Fort; Maryann Cherubini; James Cucinotta; Lee Techner Journal: Arch Surg Date: 2008-11
Authors: Mohamed Abdelgadir Adam; Lacey M Lee; Jina Kim; Mithun Shenoi; Mohan Mallipeddi; Hamza Aziz; Sandra Stinnett; Zhifei Sun; Christopher R Mantyh; Julie K M Thacker Journal: Ann Surg Date: 2016-07 Impact factor: 12.969
Authors: Emily Beth Devine; Rafael Alfonso-Cristancho; Allison Devlin; Todd C Edwards; Ellen T Farrokhi; Larry Kessler; Danielle C Lavallee; Donald L Patrick; Sean D Sullivan; Peter Tarczy-Hornoch; N David Yanez; David R Flum Journal: J Clin Epidemiol Date: 2013-08 Impact factor: 6.437
Authors: Yuxiang Wen; Murad A Jabir; Michael Keating; Alison R Althans; Justin T Brady; Bradley J Champagne; Conor P Delaney; Scott R Steele Journal: Surg Endosc Date: 2016-12-07 Impact factor: 4.584
Authors: D Ryan Phillips; Susan E Ellsperman; Bruce H Matt; Ben L Zarzaur Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-08-01 Impact factor: 6.223